Latest / The AI in Business Podcast
Where AI Should Actually Earn Its Keep in Biopharma - with Mukhtar Ahmed of Greenstone Biosciences
In biopharma R&D, AI investment has overwhelmingly targeted generating more drug candidates, even though the industry has rarely lacked for compounds worth pursuing. In this episode, Mukhtar Ahmed, Director of Project and Portfolio Strategy at Greenstone Biosciences, explores why the harder and more valuable problem is deciding which candidates deserve continued capital and attention. The conversation covers synthesizing fragmented evidence across teams, keeping human judgment and accountability in the loop, and measuring AI's impact across a portfolio rather than a single program.
Emerj…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.